Difference between revisions of "Richard Furlaud"

From Wikispooks
Jump to navigation Jump to search
(prabook)
(unstub)
 
(2 intermediate revisions by one other user not shown)
Line 1: Line 1:
 
{{person
 
{{person
 
|prabook=https://prabook.com/web/richard_mortimer.furlaud/647028
 
|prabook=https://prabook.com/web/richard_mortimer.furlaud/647028
|amazon=
+
|image=Richard Furlaud.jpg
 +
|description=[[Big Pharma]] executive responsible for making his company the global leader of the problematic drug [[statins]].
 
|alma_mater=Harvard University, Princeton University
 
|alma_mater=Harvard University, Princeton University
|nationality=
+
|nationality=US
 
|birth_date=15 April 1923
 
|birth_date=15 April 1923
 
|birth_place=New York
 
|birth_place=New York
|death_date=
+
|death_date=10 September 2018
|death_place=
+
|death_place=East Hampton, New York, USA
 
|constitutes=businessman, lawyer
 
|constitutes=businessman, lawyer
 
}}
 
}}
'''Richard Furlaud''' wsa a [[CFR]] member and worked for the Squibb Corporation.<ref>http://www.hbs.edu/leadership/20th-century-leaders/Pages/details.aspx?profile=richard_m_furlaud</ref>
+
'''Richard Mortimer Furlaud''' was an American [[pharmaceutical executive]]. He was a member of the [[CFR]].
 +
 
 +
==Career==
 +
Furlaud worked for the [[Olin Mathieson Chemical Corporation]] from 1955.
 +
 
 +
He was president, chief executive,and director for the Squibb Corporation.<ref>http://www.hbs.edu/leadership/20th-century-leaders/Pages/details.aspx?profile=richard_m_furlaud</ref> 1966-1974; and director at Squibb Corporation (merged with Bristol-Myers Company), [[New York City]], 1974-1989; president, board directors, Bristol-Myers Company (renamed Bristol-Myers Squibb Company), New York City, 1989-1991.<ref>https://prabook.com/web/richard_mortimer.furlaud/647028</ref>
 +
 
 +
Furlaud focused on Squibb's pharmaceuticals, investing in research and development that ultimately led to the introduction of several new drugs. Furlaud's streamlining and consistent support of the company's cardiovascular drugs paid off as the drugs' revenues jumped $240 million in one year. His changes at Squibb, though risky and at times controversial, allowed the firm to become a global leader in two of the [[pharmaceutical industry]]'s most lucrative and growing markets, cardiovascular and [[cholesterol-lowering drugs]]<ref>https://www.hbs.edu/leadership/20th-century-leaders/details?profile=richard_m_furlaud</ref> (i.e. the problematic [[statins]]).
 +
 
 +
 
 +
 
 
{{SMWDocs}}
 
{{SMWDocs}}
 
==References==
 
==References==
 
{{reflist}}
 
{{reflist}}
{{Stub}}
 

Latest revision as of 10:21, 18 October 2023

Person.png Richard Furlaud PrabookRdf-entity.pngRdf-icon.png
(businessman, lawyer)
Richard Furlaud.jpg
Born15 April 1923
New York
Died10 September 2018 (Age 95)
East Hampton, New York, USA
NationalityUS
Alma materHarvard University, Princeton University
Member ofCouncil on Foreign Relations/Historical Members
Big Pharma executive responsible for making his company the global leader of the problematic drug statins.

Richard Mortimer Furlaud was an American pharmaceutical executive. He was a member of the CFR.

Career

Furlaud worked for the Olin Mathieson Chemical Corporation from 1955.

He was president, chief executive,and director for the Squibb Corporation.[1] 1966-1974; and director at Squibb Corporation (merged with Bristol-Myers Company), New York City, 1974-1989; president, board directors, Bristol-Myers Company (renamed Bristol-Myers Squibb Company), New York City, 1989-1991.[2]

Furlaud focused on Squibb's pharmaceuticals, investing in research and development that ultimately led to the introduction of several new drugs. Furlaud's streamlining and consistent support of the company's cardiovascular drugs paid off as the drugs' revenues jumped $240 million in one year. His changes at Squibb, though risky and at times controversial, allowed the firm to become a global leader in two of the pharmaceutical industry's most lucrative and growing markets, cardiovascular and cholesterol-lowering drugs[3] (i.e. the problematic statins).



Many thanks to our Patrons who cover ~2/3 of our hosting bill. Please join them if you can.


References